Free Trial

Ultragenyx Pharmaceutical (RARE) News Today

Ultragenyx Pharmaceutical logo
$33.87 -1.16 (-3.31%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$34.03 +0.16 (+0.47%)
As of 05/30/2025 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RARE Latest News

Ultragenyx Pharmaceutical Inc. stock logo
Equities Analysts Offer Predictions for RARE FY2025 Earnings
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Equities research analysts at William Blair issued their FY2025 EPS estimates for Ultragenyx Pharmaceutical in a report released on Wednesday, May 28th. William Blair analyst S. Corwin expects that the biopharmaceutical company will pos
Ultragenyx Pharmaceutical Inc. stock logo
William Blair Begins Coverage on Ultragenyx Pharmaceutical (NASDAQ:RARE)
William Blair assumed coverage on Ultragenyx Pharmaceutical in a report on Wednesday. They set an "outperform" rating and a $65.00 price objective for the company.
Ultragenyx Pharmaceutical Inc. stock logo
Squarepoint Ops LLC Purchases Shares of 87,989 Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
Squarepoint Ops LLC bought a new position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 87,989 shares of the biopharmaceutical company
Ultragenyx Pharmaceutical Inc. stock logo
Twinbeech Capital LP Raises Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
Twinbeech Capital LP increased its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 531.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 33,857 shares of the biopharmaceutical company's stock after buyi
Ultragenyx Pharmaceutical Inc. stock logo
Two Sigma Investments LP Has $25.87 Million Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
Two Sigma Investments LP decreased its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 18.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 614,948 shares of the biop
Ultragenyx Pharmaceutical Inc. stock logo
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Purchased by Frazier Life Sciences Management L.P.
Frazier Life Sciences Management L.P. raised its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 3.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 658,715 shares of the
Ultragenyx Pharmaceutical Inc. stock logo
Bank of America Corp DE Has $16.34 Million Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
Bank of America Corp DE decreased its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 58.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 388,502 shares of
Ultragenyx Pharmaceutical Inc. stock logo
Two Sigma Advisers LP Sells 74,300 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
Two Sigma Advisers LP cut its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 7.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 913,500 shares of the biopharmaceutical company's stock after sellin
Ultragenyx Pharmaceutical Inc. stock logo
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is Vestal Point Capital LP's 5th Largest Position
Vestal Point Capital LP grew its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 100.0% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,500,000 shares of the biopharmaceutical company's stock af
Ultragenyx Pharmaceutical Inc. stock logo
Millennium Management LLC Sells 13,453 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
Millennium Management LLC reduced its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 1.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 697,236 shares of the biopharmaceutical company's stock after selling 1
Ultragenyx Pharmaceutical Inc. stock logo
Sherbrooke Park Advisers LLC Acquires Shares of 10,387 Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
Sherbrooke Park Advisers LLC acquired a new stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,387 shares of the bio
Ultragenyx Pharmaceutical Inc. stock logo
Man Group plc Trims Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
Man Group plc cut its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 9.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 297,394 shares of the biopharmaceutical company's
Ultragenyx Pharmaceutical Inc. stock logo
Sphera Funds Management LTD. Has $9.63 Million Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
Sphera Funds Management LTD. increased its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 17.1% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 228,776 shares of the biopharmaceutical company's stock after
Ultragenyx Pharmaceutical Inc. stock logo
Point72 Asset Management L.P. Grows Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
Point72 Asset Management L.P. raised its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 81.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,182,877 shares of the biopharmaceutical co
Ultragenyx Pharmaceutical Inc. stock logo
Point72 Hong Kong Ltd Grows Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
Point72 Hong Kong Ltd grew its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 173.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 27,399 shares of the biopharmaceutical
Ultragenyx Pharmaceutical Inc. stock logo
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Purchased by MPM Bioimpact LLC
MPM Bioimpact LLC boosted its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 18.6% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 391,018 shares of the biopharmaceutica
Ultragenyx Pharmaceutical Inc. stock logo
Parkman Healthcare Partners LLC Has $4.21 Million Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
Parkman Healthcare Partners LLC reduced its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 8.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 100,159 shares of the biopharmaceu
Ultragenyx Pharmaceutical Inc. stock logo
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Decreases Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 51.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owne
Ultragenyx Pharmaceutical Inc. stock logo
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Consensus Rating of "Moderate Buy" from Brokerages
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) have been given an average rating of "Moderate Buy" by the fifteen analysts that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and fourteen have issued
Ultragenyx Pharmaceutical Inc. stock logo
D. E. Shaw & Co. Inc. Has $12.04 Million Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
D. E. Shaw & Co. Inc. grew its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 9.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 286,079 shares of the biopharm
Ultragenyx Pharmaceutical Inc. stock logo
BNP Paribas Financial Markets Buys 113,797 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
BNP Paribas Financial Markets grew its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 394.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 142,628 shares of the biopharmaceut
Ultragenyx Pharmaceutical Inc. stock logo
Northern Trust Corp Purchases 55,641 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
Northern Trust Corp increased its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 11.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 528,965 shares of the biopharmaceutical company's stock after buying an additional 5
Ultragenyx Pharmaceutical Inc. stock logo
Hudson Bay Capital Management LP Buys 182,500 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
Hudson Bay Capital Management LP raised its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 93.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 377,500 shares of the biopharma
Ultragenyx Pharmaceutical Inc. stock logo
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Holdings Lifted by Graham Capital Management L.P.
Graham Capital Management L.P. grew its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 37.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 59,129 shares of the b
Ultragenyx Pharmaceutical Inc. stock logo
Wedbush Issues Pessimistic Estimate for RARE Earnings
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Stock analysts at Wedbush lowered their Q2 2025 earnings estimates for Ultragenyx Pharmaceutical in a research report issued on Wednesday, May 7th. Wedbush analyst L. Chico now forecasts that the biopharmaceutical company will post earn
Ultragenyx Pharmaceutical Inc. stock logo
Leerink Partnrs Has Bullish Outlook for RARE Q2 Earnings
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Leerink Partnrs boosted their Q2 2025 earnings per share (EPS) estimates for Ultragenyx Pharmaceutical in a report released on Wednesday, May 7th. Leerink Partnrs analyst J. Schwartz now anticipates that the biopharmaceutical company wi
Ultragenyx Pharmaceutical Inc. stock logo
Fred Alger Management LLC Sells 70,033 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
Fred Alger Management LLC decreased its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 13.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 466,2
Ultragenyx Pharmaceutical Inc. stock logo
DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main Raises Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 17.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 346,597 s
Ultragenyx Pharmaceutical Inc. stock logo
Driehaus Capital Management LLC Has $34.90 Million Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
Driehaus Capital Management LLC lifted its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 5.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 829,465 shares
Ultragenyx Pharmaceutical Inc. stock logo
27,949 Shares in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Bought by Crestline Management LP
Crestline Management LP acquired a new stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 27,949 shares of th
Ultragenyx Pharmaceutical Inc. stock logo
Deep Track Capital LP Buys Shares of 653,513 Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
Deep Track Capital LP purchased a new position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 653,513 shares of the biopharmaceutical company's stock, valued at appro
Ultragenyx Pharmaceutical Inc. stock logo
Brevan Howard Capital Management LP Has $1.48 Million Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
Brevan Howard Capital Management LP grew its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 116.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 35,201 shares of the biopharmaceutical company's stock
Ultragenyx Pharmaceutical Inc. stock logo
Algert Global LLC Purchases 8,891 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
Algert Global LLC boosted its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 12.0% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 82,793 shares of the biopharmaceutical company's stock aft
Ultragenyx Pharmaceutical Inc. stock logo
Cutter Capital Management LP Has $17.11 Million Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
Cutter Capital Management LP raised its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 41.8% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 406,803 shares of the biopharmaceutical company's stock after buy
Ultragenyx Pharmaceutical Inc. stock logo
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Holdings Lowered by Bamco Inc. NY
Bamco Inc. NY reduced its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 16.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 40,000 shares of the biopharmaceutical company's stock aft
Ultragenyx Pharmaceutical Inc. stock logo
AQR Capital Management LLC Trims Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
AQR Capital Management LLC reduced its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 73.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 280,547 shares of the biopharmaceutical company's stock after s
Ultragenyx Pharmaceutical Inc. stock logo
The Manufacturers Life Insurance Company Sells 21,468 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
The Manufacturers Life Insurance Company trimmed its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 9.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 216,587 shares of the
Ultragenyx Pharmaceutical Inc. stock logo
Raymond James Financial Inc. Buys New Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
Raymond James Financial Inc. bought a new stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 21,774 shares of the biopharmaceutical company's sto
Ultragenyx Pharmaceutical Inc. stock logo
Axa S.A. Boosts Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
Axa S.A. increased its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 7.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 456,588 shares of the biopharmaceutical company's stock after purchasing an a
Get Ultragenyx Pharmaceutical News Delivered to You Automatically

Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter.

RARE Media Mentions By Week

RARE Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

RARE
News Sentiment

1.11

0.87

Average
Medical
News Sentiment

RARE News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

RARE Articles
This Week

10

8

RARE Articles
Average Week

Get Ultragenyx Pharmaceutical News Delivered to You Automatically

Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:RARE) was last updated on 5/31/2025 by MarketBeat.com Staff
From Our Partners
OSZAR »